Thermo Fisher Scientific (TMO): Organic growth supports quarterly expansion
Why it is trending
Thermo Fisher's quarterly results showed stronger revenue, organic growth and operating margins. Scientific instruments, laboratory products and biopharma services remain central to its growth strategy.
Adjusted earnings advanced faster than GAAP earnings, underscoring the importance of keeping the two measures separate when assessing operating performance.
Sector
Health Care. Thermo Fisher provides scientific instruments, laboratory supplies, diagnostics and services supporting biopharmaceutical research and production.
Company information
Metric | Company profile |
Sector | Health Care |
Industry | Diagnostics & Research |
Market capitalization | $258.71 billion; October 21 intraday data |
YTD price return | +18.62% through October 20, 2026 |
Dividend yield | 0.27%; indicated annual regular dividend |
Forward P/E, one-year basis | 24.92×; FY2027 adjusted consensus EPS |
Price-dependent calculations use the October 20 regular-session close of $687.37. Market capitalization uses separately dated October 21 data. Forward estimates were last updated October 18, before the latest earnings release.
Recent earnings
Metric | Q3 2026 results |
Revenue | $12.137 billion |
Revenue growth | +9.13% year over year |
Organic revenue growth | +6% |
GAAP diluted EPS | $4.64; +8.67% year over year |
Adjusted EPS, non-GAAP | $6.68; +15% year over year |
GAAP operating margin | 18.6%, versus 17.4% a year earlier |
Earnings trend | Weakening. GAAP diluted EPS YoY growth: Q1 +11.31%, Q2 +9.35%, Q3 +8.67%. |
Sales trend | Mixed. Reported revenue YoY growth: Q1 +6.18%, Q2 +10.49%, Q3 +9.13%. |
The quarter ended September 26, 2026. Growth rates are calculated from reported figures. Weakening means slower earnings growth, not a year-over-year earnings decline. Trend labels describe historical results, not forecasts.
ATA ULTIMATE SWING ALGORITHM V2 REVIEW
TF1 DAILY: BUY BIAS (SMALL DOTS).
TF2 WEEKLY: BUY BIAS (LARGE DIAMONDS).
WE PREPARE FOR THE NEXT MOVE RATHER THAN PREDICT IT.
Wednesday October 21, 2026